Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.35 |
| ▸ | CSF1R | P07333 | 2/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.30 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.30 |
| ▸ | OXTR | P30559 | 1/20 | 0.30 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.30 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3523934 | 0.78 | EGFR (0.58) | EGFREPHA2 | |
| SCHEMBL3521877 | 0.78 | EGFR (0.58) | EGFREPHA2 | |
| SCHEMBL4673010 | 0.78 | EGFR (0.58) | EGFREPHA2 | |
| SCHEMBL1675992 | 0.78 | EGFR (0.58) | EGFREPHA2 | |
| SCHEMBL4729876 | 0.78 | EGFR (0.58) | EGFREPHA2 | |
| SCHEMBL6405839 | 0.72 | EGFR (0.49) | EGFREPHA2 | |
| SCHEMBL6407787 | 0.71 | EGFR (0.47) | EGFRCSF1RLMNAMAPK1 | |
| SCHEMBL3519725 | 0.70 | EGFR (0.60) | EGFR | |
| SCHEMBL3523105 | 0.70 | EGFR (0.60) | EGFR | |
| SCHEMBL4732808 | 0.70 | EGFR (0.60) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659279-B2 | 2-{(2S)-2-[({4-[3-Chloro-4-fluoroanilino]-7-methoxyquinazolin-5-yl}oxy)methyl]pyrrolidin-1-yl}-2-oxoethanol; epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors; breast, colorectal and head and neck cancer | ASTRAZENECA AB (SE) | 2010-02-09 | — | — | US | disclosed |
| US-20060211714-A1 | Quinazoline derivatives and their use in the treatment of cancer | ASTRAZENECA AB (SE) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211714-A1 | Quinazoline derivatives and their use in the treatment of cancer | EGFR, ERBB2, ERBB4 | EGFR 1/4885CSF1R 1149/4885GRIN2C 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.